EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The “Heater” of “Cold” Tumors–Blocking IL‐6

Weigao Pu, Chenhui Ma, Bofang Wang, Weidong Zhu iD, Hao Chen

Advanced Biology · 2024-07 · 8 (7)

DOI: 10.1002/adbi.202300587 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Biology, online erschienen am 22.05.2024. Verfasst von Weigao Pu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China. Hauptthemen laut MEDLINE: Interleukin-6, Neoplasms, Tumor Microenvironment, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Science and Technology in Gansu province, Medical Innovation and Development Project of Lanzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The resolution of inflammation is not simply the end of the inflammatory response but rather a complex process that involves various cells, inflammatory factors, and specialized proresolving mediators following the occurrence of inflammation. Once inflammation cannot be cleared by the body, malignant tumors may be induced. Among them, IL‐6, as an immunosuppressive factor, activates a variety of signal transduction pathways and induces tumorigenesis. Monitoring IL‐6 can be used for the diagnosis, efficacy evaluation and prognosis of tumor patients. In terms of treatment, improving the efficacy of targeted and immunotherapy remains a major challenge. Blocking IL‐6 and its mediated signaling pathways can regulate the tumor immune microenvironment and enhance immunotherapy responses by activating immune cells. Even transform “cold” tumors that are difficult to respond to immunotherapy into immunogenic “hot” tumors, acting as a “heater” for “cold” tumors, restarting the tumor immune cycle, and reducing immunotherapy‐related toxic reactions and drug resistance. In clinical practice, the combined application of IL‐6 inhibition with targeted therapy and immunotherapy may produce synergistic results. Nevertheless, additional clinical trials are imperative to further validate the safety and efficacy of this therapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6NeoplasmsTumor MicroenvironmentImmunotherapyInterleukin-6 InhibitorsHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

immunotherapyinflammationinterleukin‐6irAEstargeted therapytumor

Substanzen

Interleukin-6Interleukin-6 InhibitorsIL6 protein, human

Autor:innen und Institutionen

  • The Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
  • Department of Tumour Surgery, Lanzhou University Second Hospital, Lanzhou, 730030, China.
  • General Surgery Department of Lintao County People's Hospital in Gansu Province, Lanzhou, Gansu, 730030, China.
  • Gansu Provincial Key Laboratory of Environmental Oncology, Lanzhou, Gansu, 730030, China.

ORCID-Profile: Weidong Zhu

Förderung

  • National Natural Science Foundation of China
  • Key Project of Science and Technology in Gansu province
  • Medical Innovation and Development Project of Lanzhou University
  • Gansu Province Innovation Driven Assistance Project

Zitieren

APA

Pu, W., Ma, C., Wang, B., Zhu, W., & Chen, H. (2024). The “Heater” of “Cold” Tumors–Blocking IL‐6. Advanced Biology, 8(7). https://doi.org/10.1002/adbi.202300587

Vancouver

Pu W, Ma C, Wang B, Zhu W, Chen H. The “Heater” of “Cold” Tumors–Blocking IL‐6. Advanced Biology. 2024;8(7). doi:10.1002/adbi.202300587

BibTeX
@article{Pu2024,
  author = {Pu, Weigao and Ma, Chenhui and Wang, Bofang and Zhu, Weidong and Chen, Hao},
  title = {The “Heater” of “Cold” Tumors–Blocking IL‐6},
  journal = {Advanced Biology},
  year = {2024},
  volume = {8},
  number = {7},
  doi = {10.1002/adbi.202300587}
}
Kostenlos starten →